| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8fa73639d3e2c89ec8e445daf969b7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 |
| filingDate |
2021-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b2237b15fd11edb9a181d2510cb9c52 |
| publicationDate |
2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11311544-B2 |
| titleOfInvention |
Treatment of congenital adrenal hyperplasia |
| abstract |
CRF 1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11730739-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021137926-A1 |
| priorityDate |
2014-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |